BioNTech's $1 Billion Buyback and Promising Lung Cancer Data Can't Bridge the Valuation Gap
02.06.2026 - 19:12:04 | boerse-global.de
BioNTech delivered some of its most compelling oncology data to date at the American Society of Clinical Oncology meeting on June 2, yet the market response was anything but celebratory. The shares shed 3.9% on June 1, closing at €78.40, and slid a further 3.2% the following day to €76.40 — extending a year-long decline that leaves the stock roughly 23% below its 52-week high of €101.90. The disconnect between clinical progress and investor sentiment has rarely been starker.
The focus of attention was pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, which BioNTech is developing in partnership with Bristol Myers Squibb. Interim results from the global Phase 2/3 ROSETTA Lung-02 trial in first-line advanced non-small-cell lung cancer (NSCLC) showed remarkable response rates. In the Phase 2 portion, the confirmed objective response rate hit 57.1% among non-squamous patients and 68.4% in the squamous subgroup. For patients with a tumor proportion score of at least 50%, the response rate reached 100%. The disease control rate across the entire evaluable cohort was equally impressive at 100%.
But the safety profile introduced a note of caution. Grade 3 or higher adverse events occurred in 48.8% of patients, with 23.3% of those attributed specifically to pumitamig. After a median follow-up of 9.0 months, 9.3% of patients discontinued treatment due to side effects. These figures will be scrutinised closely as the programme moves into the full Phase 3 portion, where pumitamig combined with chemotherapy will go head-to-head against established standards such as Merck’s pembrolizumab.
Analysts are largely undeterred by the safety signals or the stock’s recent weakness. Jefferies reaffirmed its buy recommendation on June 1 with a price target of $138, even as the shares dropped that same day. UBS had upgraded the stock from Neutral to Buy on May 27, raising its target from $117 to $135, citing growing conviction in the oncology pipeline’s market potential. The consensus among analysts stands at “Moderate Buy” with a median price target of $129.56 — well above current trading levels.
Should investors sell immediately? Or is it worth buying BioNTech?
BioNTech is backing its conviction with a tangible shareholder commitment. A share buyback programme of up to $1 billion, representing roughly 4.2% of outstanding shares, is running through May 2027 and will be funded from existing cash reserves. At the end of March 2026, the company held approximately €16.8 billion in liquidity — a war chest accumulated during the COVID-19 vaccine era that now underwrites a sweeping oncology pivot.
The scale of that pivot is evident in the pipeline. BioNTech is currently running more than 25 Phase 2 and Phase 3 studies, including 13 pivotal registration trials. The portfolio spans not only bispecific immunomodulators and CTLA-4 antibodies like gotistobart, but also antibody-drug conjugates and mRNA-based cancer immunotherapies in both single-agent and novel combination regimens. In the NSCLC space alone, seven separate Phase 3 studies are now active, including ROSETTA Lung-02, -201 and -202.
Institutional investors appear to be positioning for a longer-term payoff. New positions are being built, even as the broader market remains unimpressed by the year-to-date slide of nearly 5% (or 7.4% depending on the trading day). The stock is barely 8% above its March low, and more than 25% off the peak reached in June 2025.
BioNTech at a turning point? This analysis reveals what investors need to know now.
The ultimate test lies ahead. Phase 2 data, however promising, must hold up in large-scale Phase 3 trials. Results from those pivotal studies are not expected until the second half of the decade at the earliest. Until then, BioNTech’s transformation from vaccine maker to oncology powerhouse will be judged less by clinical milestones and more by investors’ patience — and the gap between a €16.8 billion cash pile and a stubbornly discounted market valuation will remain the central debate.
Ad
BioNTech Stock: New Analysis - 2 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
